These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

347 related items for PubMed ID: 8508371

  • 41. Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study.
    Lilenbaum RC, Miller AA, Batist G, Bernard S, Hollis DR, Rosner GL, Egorin MJ, Schilsky RL, Ratain MJ.
    J Clin Oncol; 1998 Oct; 16(10):3302-9. PubMed ID: 9779705
    [Abstract] [Full Text] [Related]

  • 42. Carboplatin in combination as first-line therapy in advanced breast cancer.
    Brambilla C, Ferrari L, Passoni P, Bonadonna G.
    Cancer Treat Rev; 1993 Oct; 19 Suppl C():3-9. PubMed ID: 8221714
    [Abstract] [Full Text] [Related]

  • 43. Alternated approach with local irradiation and combination chemotherapy including cisplatin or carboplatin plus epirubicin and etoposide in intermediate stage non-small cell lung cancer.
    Comella P, Scoppa G, Daponte A, Musetta G, Anania C, Maiorino A, Curcio C, Casaretti R, Comella G.
    Cancer; 1994 Oct 01; 74(7):1874-81. PubMed ID: 8082093
    [Abstract] [Full Text] [Related]

  • 44. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
    van As JW, van den Berg H, van Dalen EC.
    Cochrane Database Syst Rev; 2012 May 16; (5):CD009219. PubMed ID: 22592737
    [Abstract] [Full Text] [Related]

  • 45. Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie.
    du Bois A, Lück HJ, Meier W, Möbus V, Costa S, Richter B, Bauknecht T, Warm M, Schroeder W, Olbricht S, Nitz U, Jackisch C.
    Semin Oncol; 1997 Aug 16; 24(4 Suppl 11):S11-28-S11-33. PubMed ID: 9314296
    [Abstract] [Full Text] [Related]

  • 46. Second-line chemotherapy with cisplatin-ifosfamide in patients with ovarian cancer previously treated with carboplatin-cyclophosphamide.
    Polyzos A, Tsavaris N, Kosmas C, Petrikos G, Giannikos L, Kalahanis N, Papadopoulos O, Christodoulou K, Giannakopoulos K, Veslemes M, Katsilambros N.
    J Chemother; 1999 Apr 16; 11(2):144-9. PubMed ID: 10326746
    [Abstract] [Full Text] [Related]

  • 47. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
    Harper P.
    Semin Oncol; 1997 Oct 16; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
    [Abstract] [Full Text] [Related]

  • 48. Cisplatin, carboplatin, and cyclophosphamide combination chemotherapy in advanced-stage ovarian carcinoma: an Eastern Cooperative Oncology Group pilot study.
    Grem J, O'Dwyer P, Elson P, Simon N, Trump D, Frontiera M, Falkson G, Vogl S.
    J Clin Oncol; 1991 Oct 16; 9(10):1793-800. PubMed ID: 1919629
    [Abstract] [Full Text] [Related]

  • 49. [Clinical study of topotecan and cisplatin as first line chemotherapy in epithelial ovarian cancer].
    Meng LH, Kong BH, Zhang YZ, Yang XS, Wang LJ, Su SL, Jiang J, Cui BX, Wang B.
    Zhonghua Fu Chan Ke Za Zhi; 2007 Oct 16; 42(10):683-7. PubMed ID: 18241544
    [Abstract] [Full Text] [Related]

  • 50. Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study.
    Chang AY, Boros L, Garrow GC, Asbury RF, Hui L.
    Semin Oncol; 1996 Jun 16; 23(3 Suppl 6):74-7. PubMed ID: 8677454
    [Abstract] [Full Text] [Related]

  • 51. Platinum-induced hearing loss after treatment for childhood cancer.
    van As JW, van den Berg H, van Dalen EC.
    Cochrane Database Syst Rev; 2016 Aug 03; 2016(8):CD010181. PubMed ID: 27486906
    [Abstract] [Full Text] [Related]

  • 52. A phase II study of ifosfamide, carboplatin and cisplatin in advanced and recurrent squamous cell carcinoma of the uterine cervix.
    Filtenborg TA, Hansen HH, Aage Engelholm S, Rørth M.
    Ann Oncol; 1993 Jun 03; 4(6):485-8. PubMed ID: 8353091
    [Abstract] [Full Text] [Related]

  • 53. Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer.
    Huizing MT, van Warmerdam LJ, Rosing H, Schaefers MC, Lai A, Helmerhorst TJ, Veenhof CH, Birkhofer MJ, Rodenhuis S, Beijnen JH, ten Bokkel Huinink WW.
    J Clin Oncol; 1997 May 03; 15(5):1953-64. PubMed ID: 9164207
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Simultaneous dose escalation and schedule intensification of carboplatin-based chemotherapy using peripheral blood progenitor cells and filgrastim: a phase I trial.
    Fennelly D, Wasserheit C, Schneider J, Hakes T, Reich L, Curtin J, Yao TJ, Markman M, Norton L, Crown J.
    Cancer Res; 1994 Dec 01; 54(23):6137-42. PubMed ID: 7525055
    [Abstract] [Full Text] [Related]

  • 56. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer.
    Berruti A, Terzolo M, Pia A, Angeli A, Dogliotti L.
    Cancer; 1998 Nov 15; 83(10):2194-200. PubMed ID: 9827725
    [Abstract] [Full Text] [Related]

  • 57. Paclitaxel plus carboplatin in the treatment of patients with advanced lung cancer: a Vanderbilt University Cancer Center phase II trial (LUN-46).
    Johnson DH, Paul DM, Hande KR, DeVore R.
    Semin Oncol; 1996 Dec 15; 23(6 Suppl 16):42-6. PubMed ID: 9007120
    [Abstract] [Full Text] [Related]

  • 58. High-dose platinum versus standard dose in advanced ovarian carcinoma: a randomized trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC).
    Joly F, Héron JF, Kerbrat P, Chauvergne J, Rios M, Mayer F, Chinet-Charrot P, Goupil A, Lebrun-Jezekova D, Vennin D, Lhommé C, Macé-Lesec'h J, Crouet H.
    Gynecol Oncol; 2000 Sep 15; 78(3 Pt 1):361-8. PubMed ID: 10985895
    [Abstract] [Full Text] [Related]

  • 59. Results of a Southwest Oncology Group phase III trial of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide in advanced ovarian cancer.
    Hannigan EV, Green S, Alberts DS, O'Toole R, Surwit E.
    Oncology; 1993 Nov 15; 50 Suppl 2():2-9. PubMed ID: 8233297
    [Abstract] [Full Text] [Related]

  • 60. Escalating sequential high-dose carboplatin and etoposide with autologous marrow support in children with relapsed solid tumors.
    Santana VM, Schell MJ, Williams R, Bowman LC, Thompson EI, Brenner MK, Mirro J.
    Bone Marrow Transplant; 1992 Nov 15; 10(5):457-62. PubMed ID: 1464010
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.